HER2 expression in cervical cancer as a potential therapeutic target
<p>Abstract</p> <p>Background</p> <p>Trastuzumab, a humanized monoclonal antibody against the HER2 receptor is currently being used in breast and other tumor types. Early studies have shown that a variable proportion of cervical carcinoma tumors overexpress the HER2 receptor as evaluated by diverse...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
BMC
2004-09-01
|
| Rangatū: | BMC Cancer |
| Urunga tuihono: | http://www.biomedcentral.com/1471-2407/4/59 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|